Product Name :
Cangrelor tetrasodium
Description:
Cangrelor tetrasodium, an adenosine triphosphate analogue, is a reversible and selective platelet P2Y12 antagonist, with prompt and potent antiplatelet effects. Cangrelor tetrasodium directly blocks adenosine diphosphate (ADP)-induced activation and aggregation of platelets. Cangrelor tetrasodium is also a nonspecific GPR17 antagonist.
CAS:
163706-36-3
Molecular Weight:
864.29
Formula:
C17H21Cl2F3N5Na4O12P3S2
Chemical Name:
tetrasodium {dichloro[({[(2R,3S,4R,5R)-3,4-dihydroxy-5-(6-{[2-(methylsulfanyl)ethyl]amino}-2-[(3,3,3-trifluoropropyl)sulfanyl]-9H-purin-9-yl)oxolan-2-yl]methyl phosphonato}oxy)(oxido)phosphoryl]methyl}phosphonate
Smiles :
[Na+].[Na+].[Na+].[Na+].CSCCNC1=NC(=NC2=C1N=CN2[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)C(Cl)(Cl)P([O-])([O-])=O)[C@@H](O)[C@H]1O)SCCC(F)(F)F
InChiKey:
COWWROCHWNGJHQ-OPKBHZIBSA-J
InChi :
InChI=1S/C17H25Cl2F3N5O12P3S2.4Na/c1-43-5-3-23-12-9-13(26-15(25-12)44-4-2-16(20,21)22)27(7-24-9)14-11(29)10(28)8(38-14)6-37-42(35,36)39-41(33,34)17(18,19)40(30,31)32;;;;/h7-8,10-11,14,28-29H,2-6H2,1H3,(H,33,34)(H,35,36)(H,23,25,26)(H2,30,31,32);;;;/q;4*+1/p-4/t8-,10-,11-,14-;;;;/m1.{{Biotin Hydrazide} medchemexpress|{Biotin Hydrazide} {Biochemical Assay Reagents}|{Biotin Hydrazide} Purity & Documentation|{Biotin Hydrazide} In Vivo|{Biotin Hydrazide} manufacturer|{Biotin Hydrazide} Autophagy} .{{Tegafur} MedChemExpress|{Tegafur} Cell Cycle/DNA Damage|{Tegafur} Protocol|{Tegafur} In stock|{Tegafur} custom synthesis|{Tegafur} Autophagy} ../s1
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
Cangrelor tetrasodium, an adenosine triphosphate analogue, is a reversible and selective platelet P2Y12 antagonist, with prompt and potent antiplatelet effects. Cangrelor tetrasodium directly blocks adenosine diphosphate (ADP)-induced activation and aggregation of platelets. Cangrelor tetrasodium is also a nonspecific GPR17 antagonist.|Product information|CAS Number: 163706-36-3|Molecular Weight: 864.29|Formula: C17H21Cl2F3N5Na4O12P3S2|Chemical Name: tetrasodium {dichloro[({[(2R,3S,4R,5R)-3,4-dihydroxy-5-(6-{[2-(methylsulfanyl)ethyl]amino}-2-[(3,3,3-trifluoropropyl)sulfanyl]-9H-purin-9-yl)oxolan-2-yl]methyl phosphonato}oxy)(oxido)phosphoryl]methyl}phosphonate|Smiles: [Na+].[Na+].[Na+].[Na+].CSCCNC1=NC(=NC2=C1N=CN2[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)C(Cl)(Cl)P([O-])([O-])=O)[C@@H](O)[C@H]1O)SCCC(F)(F)F|InChiKey: COWWROCHWNGJHQ-OPKBHZIBSA-J|InChi: InChI=1S/C17H25Cl2F3N5O12P3S2.4Na/c1-43-5-3-23-12-9-13(26-15(25-12)44-4-2-16(20,21)22)27(7-24-9)14-11(29)10(28)8(38-14)6-37-42(35,36)39-41(33,34)17(18,19)40(30,31)32;;;;/h7-8,10-11,14,28-29H,2-6H2,1H3,(H,33,34)(H,35,36)(H,23,25,26)(H2,30,31,32);;;;/q;4*+1/p-4/t8-,10-,11-,14-;;;;/m1.PMID:23800738 …/s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: H2O : 250 mg/mL (289.25 mM; Need ultrasonic).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|Cangrelor tetrasodium is the only potent intravenous direct and specific adenosine diphosphate (ADP) P2Y12 receptor antagonist. Cangrelor tetrasodium has pKb of 8.6-9.2 for hP2Y12 receptor.|In Vivo:|Cangrelor tetrasodium (10 mg/kg) not only significantly decreases BLM-induced release of inflammatory cytokines (PF4, CD40 L and MPO), but also decreases the increment of platelets, neutrophils and platelet-neutrophil aggregates in the fibrotic lung and in the peripheral blood of BLM-treated mice.|Products are for research use only. Not for human use.|